Safety of antipsychotic drugs: focus on therapeutic and adverse effects
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of antipsychotic drugs: focus on therapeutic and adverse effects
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 13, Issue 8, Pages 1031-1042
Publisher
Informa Healthcare
Online
2014-06-30
DOI
10.1517/14740338.2014.935761
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Weight Change and Metabolic Effects of Asenapine in Patients With Schizophrenia and Bipolar Disorder
- (2014) David E. Kemp et al. JOURNAL OF CLINICAL PSYCHIATRY
- Early improvement as a predictor of treatment response and remission in patients with schizophrenia: A pooled, post-hoc analysis from the asenapine development program
- (2014) Stefan Leucht et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study
- (2014) Gunilla Ringbäck Weitoft et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial
- (2014) Suresh Durgam et al. SCHIZOPHRENIA RESEARCH
- Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy
- (2013) Leslie Citrome ADVANCES IN THERAPY
- Long-Acting Injectable Antipsychotics and the Development of Postinjection Delirium/Sedation Syndrome (PDSS)
- (2013) Vladan Novakovic et al. CLINICAL NEUROPHARMACOLOGY
- Hyperprolactinémies induites par les antipsychotiques : physiopathologie, clinique et surveillance
- (2013) I. Besnard et al. ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
- Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability
- (2013) Leslie Citrome Expert Opinion on Drug Metabolism & Toxicology
- The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis
- (2013) Jong-Il Park et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo
- (2013) Stephen M. Stahl et al. JOURNAL OF CLINICAL PSYCHIATRY
- Risk of Cardiovascular Morbidity With Risperidone or Paliperidone Treatment
- (2013) Srihari Gopal et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study
- (2013) Henry A. Nasrallah et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Movement Disorders in Elderly Users of Risperidone and First Generation Antipsychotic Agents: A Canadian Population-Based Study
- (2013) Irina Vasilyeva et al. PLoS One
- Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year
- (2013) Benedicto Crespo-Facorro et al. PSYCHOPHARMACOLOGY
- Pharmacokinetic–pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score
- (2013) Venkatesh Pilla Reddy et al. SCHIZOPHRENIA RESEARCH
- Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: A pooled analysis
- (2013) Steven G. Potkin et al. SCHIZOPHRENIA RESEARCH
- Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary
- (2013) Lajos Katona et al. SCHIZOPHRENIA RESEARCH
- Population Pharmacokinetic/Pharmacodynamic Model of Clozapine for Characterizing the Relationship Between Accumulated Exposure and PANSS Scores in Patients With Schizophrenia
- (2013) De-Wei Shang et al. THERAPEUTIC DRUG MONITORING
- A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
- (2013) Robert Bodén et al. Neuropsychiatric Disease and Treatment
- A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia
- (2013) Silvio Caccia et al. Therapeutics and Clinical Risk Management
- Antipsychotic-Induced Sexual Dysfunction and Its Management
- (2013) Yeon Won Park et al. World Journal of Mens Health
- Asenapine: A Clinical Review of a Second-Generation Antipsychotic
- (2012) Steven C. Stoner et al. CLINICAL THERAPEUTICS
- Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability
- (2012) Leslie Citrome Expert Opinion on Drug Metabolism & Toxicology
- Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable
- (2012) Erica J. Duncan et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Meta-Analyses of the Efficacy of Asenapine for Acute Schizophrenia
- (2012) Armin Szegedi et al. JOURNAL OF CLINICAL PSYCHIATRY
- Adverse Effects of Cognitive Behavioral Therapy and Cognitive Remediation in Schizophrenia
- (2012) Stefan Klingberg et al. JOURNAL OF NERVOUS AND MENTAL DISEASE
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
- (2010) Christine Rummel-Kluge et al. SCHIZOPHRENIA RESEARCH
- Asenapine
- (2009) Juliane Weber et al. CNS DRUGS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search